Klausner Requests Funds for Five Important 'Investment Opportunities' in Cancer Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

WASHINGTON--In an unusual budgetary maneuver, NCI director Richard Klausner, MD, has asked Congress to give the Institute an added $269.5 million in fiscal year 1998 to fund "extraordinary opportunities for new investments" in the battle against cancer.

WASHINGTON--In an unusual budgetary maneuver, NCI director RichardKlausner, MD, has asked Congress to give the Institute an added$269.5 million in fiscal year 1998 to fund "extraordinaryopportunities for new investments" in the battle againstcancer.

As the request of Congress, NCI prepared a budget estimate anda description of its research needs for fiscal years 1997 and1998. Dr. Klausner publicly released the 80-page document lastmonth at a talk to the D.C. Science Writers Association.

In fiscal 1996, which ends Sept. 30, the NCI's budget totals $2.251billion. The White House has asked Congress to give the institute$2.281 billion for fiscal 1997.

Dr. Klausner's budget proposal for fiscal 1998 requests $2.702billion. This includes $2.433 billion for what he calls a "maintenancebudget," aimed at keeping NCI activities at the same level,plus an additional $269.5 million for five "investment opportunities"in cancer genetics, preclinical cancer models, detection technologies,developmental diagnostics, and investigator-initiated research.

The report sets goals for each of the five targeted areas (seetable).

Specific Milestones

The five "opportunity" areas emerged over the last 6months from a series of meetings with scientists, educators, andcommunity leaders to discuss the state of cancer research, Dr.Klausner said. "They had to be things we could describe interms of specific milestones we can achieve and not promises wecan't keep," he added.

The NCI report states that these investment opportunities representfive important areas where funding is insufficient "to exploita particular research development." Dr. Klausner noted thatthe five areas were not opportunities until recently. "Forexample, we didn't know how to think about molecular diagnosisof cancer a few years ago. Now we do."

Copies of the report--The Nation's Investment in Cancer Research:A Budget Proposal for Fiscal Years 1997/98--are available by calling800-422-6237.

The NCI's Goals for Its Five 'Investment Opportunities'

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content